| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 19,519 | 16,585 | ||
| Accounts receivable, net of allowance for credit losses of 260 and 335 at september30, 2025 and december31, 2024, respectively | 32,227 | 33,512 | ||
| Taxes receivable | 1,747 | 646 | ||
| Prepaid expenses and other assets | 2,827 | 3,337 | ||
| Total current assets | 56,320 | 54,080 | ||
| Property and equipment, net | 119 | 134 | ||
| Goodwill | 70,869 | 70,869 | ||
| Patent rights, net | 5,013 | 5,181 | ||
| Technology assets, net | 7,382 | 7,677 | ||
| Tradename and customer relationships, net | 30,042 | 30,634 | ||
| Operating lease right of use assets | 481 | 528 | ||
| Security deposits and other assets | 95 | 162 | ||
| Total other assets | 113,882 | 115,051 | ||
| Total assets | 170,321 | 169,265 | ||
| Current portion of long-term debt | 3,300 | 3,300 | ||
| Accounts payable | 2,037 | 1,982 | ||
| Accrued expenses | 10,198 | 12,491 | ||
| Revenue share payable | 2,329 | 2,591 | ||
| Taxes payable | 0 | 0 | ||
| Current portion of lease liabilities | 207 | 209 | ||
| Deferred revenue | 395 | 484 | ||
| Total current liabilities | 18,466 | 21,057 | ||
| Long-term debt, net | 24,801 | 25,127 | ||
| Lease liabilities, net of current portion | 300 | 339 | ||
| Deferred tax liabilities, net | 4,491 | 3,458 | ||
| Total liabilities | 48,058 | 49,981 | ||
| Common stock, 0.001 par value, 166,666,667 shares authorized, 20,333,839 and 20,194,697 shares issued at september30, 2025 and december31, 2024, respectively | 20 | 20 | ||
| Treasury stock, 0.001 par value, 1,741,397 shares held at september30, 2025 and december31, 2024 | 2 | 2 | ||
| Additional paid-in-capital | 206,501 | 204,301 | ||
| Accumulated deficit | -84,256 | -85,035 | ||
| Total stockholders equity | 122,263 | 119,284 | ||
| Total liabilities and stockholders equity | 170,321 | 169,265 | ||
OptimizeRx Corp (OPRX)
OptimizeRx Corp (OPRX)